5 March 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the use of pembrolizumab in combination with platinum- and fluoropyrimidine-based chemotherapy in the NHS in England.

For the time being, the use of pembrolizumab in combination with platinum- and fluoropyrimidine-based chemotherapy is not recommended for the first-line treatment of adults with locally advanced unresectable or metastatic, HER2 negative gastric or gastro-oesophageal junction adenocarcinoma whose tumours express PD-L1 with a combined positive score of 1 or more.

Read NICE draft guidance consultation